FUJIFILM AND NATIONAL BREAST CANCER FOUNDATION CELEBRATE INSTALL OF MAMMOGRAPHY SYSTEM AT WHITE MEMORIAL MEDICAL CENTER

On March 24, 2016 White Memorial Medical Center, a member of the Adventist Health System and a 353-bed hospital in downtown Los Angeles, reported the installation of a new mammography system donated by FUJIFILM Medical Systems U.S.A., Inc. and National Breast Cancer Foundation (NBCF) on March 23, 2016 (Press release, Fujifilm, MAR 24, 2016, View Source [SID:1234509930]). A ceremony unveiled Fujifilm’s Aspire Cristalle at White Memorial Medical Center that will help meet the screening needs of women and assist medical professionals in the early detection and diagnosis of breast cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to be working with National Breast Cancer Foundation and White Memorial Medical Center to make a contribution that will have both immediate and long-term impacts on improving breast health care in the community," said Johann Fernando, Chief Operating Officer, FUJIFILM Medical Systems U.S.A., Inc.

According to the National Cancer Institute, 1 in 8 women will be diagnosed with breast cancer in their lifetime. Early detection and treatment are among the most effective ways to overcome cancer. The latest technology at White Memorial Medical Center will assist radiologists in screening and diagnosis of breast cancer.

"The incredible support we receive from National Breast Cancer Foundation makes a big difference at White Memorial Medical Center," said John Raffoul, President and CEO, White Memorial Medical Center. "This year alone, thanks to support from NBCF and other generous donors, we will be able to provide more than 2,300 free clinical breast exams/mammograms to underserved women of our community, of whom 45 will unfortunately test positive for cancer. This state-of-the-art equipment from Fujifilm will literally allow us to save the lives of women when we can diagnose them at an early stage of breast cancer. We are blessed to have these incredible partners supporting our hospital."

Since 2006, Fujifilm has donated $1.6 million to NBCF. The support has allowed NBCF to provide thousands of mammograms and early detection services to women in all 50 states and helped ensure that those facing breast cancer have access to quality healthcare.

"Through the donation of the Aspire Cristalle mammography system, Fujifilm will provide life-saving mammograms to women throughout the Los Angeles area," said Janelle Hail, NBCF Co-Founder & CEO. "We thank them for their partnership and support of our mission of Helping Women Now to those affected by breast cancer."

Over 9,000 worldwide facilities trust Fujifilm’s full-field digital mammography solutions, making Fujifilm the most popular digital mammography system provider in the world. To learn more about Fujifilm’s women’s health care products, please visit www.fujifilmhealthcare.com

Idiopathic Acquired Osteosclerosis in a Middle-Aged Woman with Systemic Lupus Erythematosus.

Widely distributed osteosclerosis is an unusual radiographic finding with multiple causes. A 42-year-old pre-menopausal Spanish woman gradually acquired dense bone diffusely affecting her axial skeleton and focally affecting her proximal long bones. Systemic lupus erythematosus diagnosed in adolescence had been well controlled. She had not fractured or received antiresorptive therapy, and was hepatitis C virus antibody negative. Family members had low bone mass. Lumbar spine BMD measured by dual-photon absorptiometry at age 17 years, while receiving glucocorticoids, was 79% the average value of age-matched controls. From ages 30 to 37 years, DXA BMD z-scores steadily increased in her lumbar spine from +3.8 to +7.9, and femoral neck from -1.4 to -0.7. Serum calcium and phosphorus levels were consistently normal, 25OHD <20 ng/mL, and PTH sometimes slightly increased. Her reduced eGFR was 38-55 mls/min. Hypocalciuria likely reflected positive mineral balance. During increasing BMD, turnover markers (serum bone-ALP, PINP, osteocalcin, and CTX, and urinary NTX) were 1.6- to 2.8-fold above the reference limits. Those of bone formation seemed increased more than those of resorption. FGF-23 was slightly elevated, perhaps from kidney disease. Serum OPG and TGFβ1 levels were normal, but sclerostin (SOST) and RANKL were elevated. Serum multiplex biomarker profiling confirmed a high level of SOST and RANKL, whereas DKK-1 seemed low. Matrix metalloproteinases-3 and -7 were elevated. Iliac crest biopsy revealed tetracycline labels, no distinction between thick trabeculae and cortical bone, absence of peritrabecular fibrosis, few osteoclasts, and no mastocytosis. Then, for the past three years, BMD z-scores steadily decreased. Skeletal fluorosis, mastocytosis, myelofibrosis, hepatitis C-associated osteosclerosis, multiple myeloma, and aberrant phosphate homeostasis did not explain her osteosclerosis. Mutation analysis of the LRP5, LRP4, SOST, and osteopetrosis genes was negative. Microarray showed no notable copy number variation. Perhaps her osteosclerosis reflected an interval of autoimmune-mediated resistance to SOST and/or RANKL. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


NF-κB transcriptional activation by TNFα requires phospholipase C, extracellular signal-regulated kinase 2 and poly(ADP-ribose) polymerase-1.

The nuclear enzyme poly(ADP-ribose) polymerase-1 (PARP-1) is required for pro-inflammatory effects of TNFα. Our previous studies demonstrated that PARP-1 mediates TNFα-induced NF-κB activation in glia. Here, we evaluated the mechanisms by which TNFα activates PARP-1 and PARP-1 mediates NF-κB activation.
Primary cultures of mouse cortical astrocytes and microglia were treated with TNFα and suitable signaling pathway modulators (pharmacological and molecular). Outcome measures included calcium imaging, PARP-1 activation status, NF-κB transcriptional activity, DNA damage assesment and cytokine relesease profiling.
TNFα induces PARP-1 activation in the absence of detectable DNA strand breaks, as measured by the PANT assay. TNFα-induced transcriptional activation of NF-κB requires PARP-1 enzymatic activity. Enzymatic activation of PARP-1 by TNFα was blocked in Ca(2+)-free medium, by Ca(2+) chelation with BAPTA-AM, and by D609, an inhibitor of phoshatidyl choline-specific phospholipase C (PC-PLC), but not by thapsigargin or by U73112, an inhibitor of phosphatidyl inisitol-specific PLC (PI -PLC). A TNFR1 blocking antibody reduced Ca(2+) influx and PARP-1 activation. TNFα-induced PARP-1 activation was also blocked by siRNA downregulation of ERK2 and by PD98059, an inhibitor of the MEK / ERK protein kinase cascade. Moreover, TNFα-induced NF-κB (p65) transcriptional activation was absent in cells expressing PARP-1 that lacked ERK2 phosphorylation sites, while basal NF-κB transcriptional activation increased in cells expressing PARP-1 with a phosphomimetic substitution at an ERK2 phophorylation site.
These results suggest that TNFα induces PARP-1 activation through a signaling pathway involving TNFR1, Ca(2+) influx, activation of PC-PLC, and activation of the MEK1 / ERK2 protein kinase cascade. TNFα-induced PARP-1 activation is not associated with DNA damage, but ERK2 mediated phosphorylation of PARP-1.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


Patterns of Care in Patients with Metastatic Renal Cell Carcinoma Among a U.S. Payer Population with Commercial or Medicare Advantage Membership.

Several systemic therapies are now approved for first- and second-line treatment of metastatic renal cell carcinoma (mRCC). Although the National Comprehensive Cancer Network (NCCN) guidelines offer physicians evidence-based recommendations for therapy, there are few real-world studies to help inform the utilization of these agents in clinical practice.
To (a) describe the patterns of use associated with systemic therapies for mRCC among Humana members in the United States diagnosed with mRCC, (b) assess consistency with the NCCN guidelines for treatment, and (c) to describe the initial first-line therapy regimen by prescriber specialty and site of care.
This was a retrospective study using Humana’s claims database of commercially insured patients and patients insured by the Medicare Advantage Prescription Drug plan. The study period was from January 1, 2007, to December 31, 2013. Patients with mRCC were identified by ICD-9-CM codes 189.0/189.1 and 196.xx to 199.xx; all patients were between 18 and 89 years of age, had received systemic therapy for their disease, and were followed up for 180 days. Outcome measures included choice of initial systemic therapy, starting and ending doses, first-line treatment persistence and compliance, and choice of second-line therapy. Persistence was measured using time to discontinuation of first-line therapy and proportion of days covered (PDC; the ratio of [total days of drug available minus days of supply of last prescription] to [last prescription date minus first prescription date]). Compliance was measured using the medication possession ratio (MPR; the ratio of [total days supply minus days supply of last prescription] to [last prescription date minus first prescription date]).
A total of 649 patients met all inclusion criteria; 109 were insured by commercial plans and 540 were insured by Medicare. The mean ± SD age of patients was 68.6 ± 9.4 years, and 68.6% were male; Medicare patients were older than commercial patients (71.7 ± 7.4 vs. 56.6 ± 9.1 years, respectively; P < 0.001). The most common comorbidities among the patient population were hypertension, hyperlipidemia, diabetes, and heart disease. The majority of patients (68.6%) received an oral tyrosine kinase inhibitor (TKI) as their first line of therapy: 43.9% received sunitinib, 14.0% received sorafenib, 10.0% received pazopanib, and 0.6% received axitinib. Mean ± SD time to discontinuation of first-line TKI treatment was 169.1 ± 29.5 days with sunitinib, 160.3 ± 41.1 days with pazopanib, and 160.1 ± 41.4 days with sorafenib. Other first-line therapies included inhibitors of mammalian target of rapamycin (mTOR) (19.7%) and the antivascular endothelial growth factor agent bevacizumab (9.4%). Among patients receiving mTOR inhibitors, 14.8% were started on temsirolimus and 4.9% were started on everolimus. The median starting and ending doses were the same for each drug except for sunitinib. Mean ± SD times to discontinuation of temsirolimus, everolimus, and bevacizumab were 171.8 ± 26.2, 137.0 ± 62.2, and 150.8 ± 56.0 days, respectively. Persistence on first-line regimen as measured by PDC was high (PDC ≥ 80%) for 89% of oral therapies and 77% of injectable therapies; first-line compliance was high (MPR ≥ 80%) for 77% of oral therapies and 68% of injectables. Among patients who received second-line therapy, the most common regimen was everolimus (29.2%), followed by bevacizumab (19.8%), temsirolimus (15.6%), and sunitinib (13.6%). Specialty codes obtained from the database provider identified internal medicine specialists and oncologists as the most common prescribers of TKIs and mTOR inhibitors.
Patterns of use were similar for each of the prescribed systemic treatments for mRCC, and the majority of patients were highly persistent and compliant with first-line therapies. Time to treatment discontinuation was slightly longer with oral agents compared with injectable drugs.
This study was supported by GlaxoSmithKline (GSK); pazopanib is an asset of Novartis AG as of March 1, 2015. Miller is an employee of Sanofi with stock/stock options and was an employee of GSK at the time of this study. Stemkowski, Saverno, Lane, and Tao are employees of Comprehensive Health Insights, Humana, which was contracted and paid by GSK to conduct the study. Hackshaw is an employee of Novartis and was an employee of GSK with stock/stock options at the time of this study. Loy is an employee of Humana with stock/stock options. Study concept and design were contributed by Miller, Saverno, Hackshaw, and Loy. Data collection was done by Stemkowski, Lane, and Tao, and data interpretation was performed by Miller, Stemkowski, Lane, Tao, Hackshaw, and Loy. The manuscript was written and revised by Miller, Stemkowski, Saverno, Lane, Tao, Hackshaw, and Loy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


Varian Honors Commitment to Algeria by Opening New Office in Country

On March 24, 2016 Varian Medical Systems (NYSE: VAR), leader in radiotherapy systems and software for the treatment of cancer, reported the official opening of a new strategic operating entity in Algeria, providing support to customers across North Africa (Press release, Varian Medical Systems, MAR 24, 2016, View Source [SID:1234509932]). The Algerian Minister of Health’s chief of staff and the U.S. Chief of Mission in Algeria joined with local dignitaries and senior Varian personnel at an inauguration ceremony today to mark the launch of Varian Medical Systems Algeria SPA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Varian is proud to meet our commitment to the Algerian Ministry of Health and the country’s clinical community by creating a strategic hub here in Algiers," said Fouad Rahal, managing director of VMS Algeria SPA. "Since we created the new entity nearly a year ago, we have established a facility and hired highly trained Algerian technical service, clinical applications, logistics and other experts to support cancer clinics here."

The new Varian facility in the Hydra district of Algiers employs 16 people and houses a training and education center, a parts depot and a service center. "This entity will provide clinics with a high level of service as well as offering educational programs to train clinicians on the use of Varian technology to deliver advanced radiotherapy for the benefit of Algerian cancer patients," added Rahal.

At today’s inauguration ceremony, former Minister of Health and head of the Algeria National Cancer Plan Professor Messaoud Zitouni presented on global and regional cancer trends and discussed the importance of collaboration with Varian in helping to address a growing cancer burden.

Burt Lang, Varian’s senior managing director in Africa, said, "The incidence of cancer is unfortunately growing rapidly in Africa and has become one of the continent’s top healthcare concerns. Radiotherapy plays a vital and cost effective role in treating cancer and we are committed to making it available to more patients across the continent."

The first Varian linear accelerator was installed in Algeria over 20 years ago and the company now has 21 systems operating across the country. Eighteen months ago, Varian announced that it had entered into an agreement with the Algerian Ministry of Health to equip six cancer treatment centers with advanced technology for radiotherapy and radiosurgery. The first six of these systems, including advanced TrueBeam treatment devices, are due to be installed by the end of this year.